A Randomized Double Blind Placebo Controlled Clinical Study to Assess Blood-Borne Autologous Angiogenic Cell Precursors Therapy in Patients With Critical Limb Ischemia
Phase of Trial: Phase II
Latest Information Update: 04 Sep 2017
At a glance
- Drugs ACP 01 (Primary)
- Indications Peripheral ischaemia
- Focus Therapeutic Use
- Sponsors Hemostemix
- 01 Sep 2016 Status changed from suspended to recruiting, as per Hemostemix media release.
- 01 Sep 2016 According to a Hemostemix media release, data collection and patient follow-up are ongoing. Company anticipate to continue with the enrollment of new patients in September without compromising patient safety or data integrity. The termination of the Criterium contract is not impacting our ability to continue with the trial. Company is enabling much faster enrollment in the future through rapid expansion of the number of trial sites.
- 28 Jun 2016 Status changed from recruiting to suspended, as per Hemostemix media release.